I mean, me as a little insignificant player with my lowly cash-reserves, I'll wait until we get closer.
But if I were an institutional with plenty of other people's cash to play with then I would add or open a position as they can more comfortably ride the wave to 1H 2020. And at a market cap of 110 million, even potential dilution would bring it to about 100 million, so it wouldn't make much of a difference to them to get in now or later, and you've got to be in it to win it.
They mention the 1H 2019, so net 6 months for a hoped for ARS contract on R19, so again as an institutional why not get in now.
On the milestone slide Yaky gave he also noted for ARS Pivotal Data in 2H 2019, but there isn't a milestone indicating "initiating ARS Pivotal Trial" so would this mean the trial has begun. I mean the Hip-Fracture study started a few months back and we only found out today, so could the Pivotal ARS have started already?? Seems unlikely to me though.
As mentioned to SrdghJack, if you see the slide with the patient's wound healing, it's quite astounding. Particularly one of the patients with a 10cm square of black flesh on his/her heel seeing a 95% reduction down to 0.5cm squared and disappearance of the black flesh in 8 weeks. It would be incredible to imagine that the extent and duration this patient was suffering from PAD to category R5, to then be almost devoid of wounds following 8 weeks from treatment cannot be related to the body just suddenly in that same time period deciding to heal itself and provide more blood flood and oxygen to the foot. As the KOL mentioned there must be a physiological change happening there.
As an institutional, I would see reason to buy in now.
